"Innovative medicine for everyone, everywhere"
Listed on the Euronext stock market, Adocia is a clinical-stage biotech company specialized in the development of best-in-class medicine relying on innovative formulations of already-approved therapeutic proteins. Adocia operates in the diabetes and metabolic disease field.
The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients.
For more information, visit our website: www.adocia.com
For careers offers, please click to the following link : http://offres.adocia.com/en
Listed on the Euronext stock market, Adocia is a clinical-stage biotech company specialized in the development of best-in-class medicine relying on innovative formulations of already-approved therapeutic proteins. Adocia operates in the diabetes and metabolic disease field.
The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients.
For more information, visit our website: www.adocia.com
For careers offers, please click to the following link : http://offres.adocia.com/en
Location: France, Auvergne-Rhône-Alpes, Lyon
Employees: 51-200
Total raised: $49.84M
Founded date: 2005
Investors 2
| Date | Name | Website |
| - | Idinvest P... | idinvest.c... |
| 24.08.2022 | IPF Partne... | ipfpartner... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 11.12.2019 | - | $49.84M | - |
Mentions in press and media 8
| Date | Title | Description |
| 16.09.2024 | «Оземпик» превратили в гидрогель.Его не надо колоть еженедельно, а достаточно нанести раз в месяц | Исследователи из Франции разработали систему введения семаглутида один раз в месяц на основе гидрогеля, что значительно упрощает лечение диабета и контроль веса. Она будет представлена на ежегодном собрании Европейской ассоциации по изучени... |
| 06.01.2022 | Adocia announces its financial calendar for 2022 | LYON, France, Jan. 06, 2022 (GLOBE NEWSWIRE) -- ADOCIA SA, a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical stage biopharmaceutical company focused on diabetes trea... |
| 06.01.2022 | Adocia announces its financial calendar for 2022 | LYON, France, Jan. 06, 2022 (GLOBE NEWSWIRE) -- ADOCIA SA, a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical stage biopharmaceutical company focused on diabetes trea... |
| 14.10.2021 | Adocia’s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial to Treat Type 1 and Type 2 Diabetes in China | This Phase 3 clinical program will enroll over 1,300 people with diabetes and is expected to be pivotal for product registration in ChinaFirst patient in the study will trigger a milestone payment to AdociaBC Lispro addresses the Chinese pr... |
| 14.10.2021 | Adocia :'s Partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial to Treat Type 1 and Type 2 Diabetes in China | This Phase 3 clinical program will enroll over 1,300 people with diabetes and is expected to be pivotal for product registration in ChinaFirst patient in the study will trigger a milestone payment to AdociaBC Lispro addresses the Chinese pr... |
| 15.06.2021 | ADOCIA ADOCIA Announces M1Pram Clinical Data Presentation at the American Diabetes Association® 81ˢᵗ Scientific Sessions | LYON, France, June 15, 2021 (GLOBE NEWSWIRE) -- ADOCIA (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company specializing in the development of innovative formulations of proteins and peptides, announced today Ad... |
| 11.05.2021 | ADOCIA : Announces the Live Broadcast of its Annual General Meeting on May 20th, 2021 | Regulatory News: ADOCIA (Paris:ADOC) (Euronext Paris: FR0011184241 – ADOC – the company) a clinical stage biopharmaceutical company focused on diabetes treatment with innovative formulations of approved proteins, confirms that it will hold ... |
| 27.01.2010 | France, Adocia Raises €14M in Second Venture Funding Round | Adocia, a Lyon, France-based biotechnology company specialized in protein delivery, has raised €14m in its second round of funding. Investors in the round include: – the biotech fund Fonds InnoBio, managed by CDC Enterprises within the fram... |